Companies · Biotechnology

Single Cell Technology, Inc.

SAN JOSE · Biotechnology

Diligence memoA one-page analyst read on Single Cell Technology, Inc. — recommendation, valuation, rhythm, risks.
$2.5M
Total raised · real
2
Rounds
20.3×
Latest step-up
Top 70%
Sector rank · raised
Seed
Latest stage · inferred · Fri Jan 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Single Cell Technology, Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.08× the median modeled value of Seed Biotechnology companies in 2019–2021 (186 peers) — value vs value, same stage and era.
  • Within the normal band (108% of peer median) for its niche.
Dormant
  • Last raise 5.4 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Single Cell Technology, Inc. is one of 4291 Biotechnology companies tracked from SAN JOSE. By capital raised it ranks in the long tail (ahead of 31% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
$1M–$5M
Issuer revenue
Rule 506(b)
Reg D exemption
15
Investors (latest)
2021-01-22
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$25M$50M$75M$100MPre-Seed · 2012-12-12 Raised $324K (real) Modeled valuation $18M (est)$324K$18MPre-Seed2012Pre-Seed · 2012-12-12 Raised $105K (real) Modeled valuation $5.8M (est)$105K$5.8MPre-Seed2012Seed · 2021-01-22 Raised $2.1M (real) Modeled valuation $69M (est)$2.1M$69MSeed2021+$105K+$2.1MCumulative $2.6M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$324K · 2012
Pre-Seed extension$105K · 2012
Seed$2.1M · 2021

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$69.4M
Base estimate est.
$1.5M
Conservative case
$467.9M
Upside case
$10.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $17.9M · 2012-12-122012Pre-Seed · modeled $5.8M · 2012-12-12Seed · modeled $69.4M · 2021-01-222021
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
32%
Survival probability
14% low · 50% high
1.74×/yr
Annual markup
2.28×/yr upside case
5.4 yr
Elapsed time used
5.4 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
49 mo
Avg between rounds
$303K/yr
Capital velocity
13.6 yr
On record since
2012
First round
3
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.3× of median
This company$2.5M
Sector median$7.2M
Latest round — vs other Seed rounds in sector (real $, this stage) 1.2× above median
This company$2.1M
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 1.1× above median
This company$69.4M
Sector median$64.2M

Raised more than 31% of sector peers (real $). Modeled value above 52% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #73 of 186.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0MCapital raised (log)Entac Medical, Inc. · Seed Raised $4.0M · modeled $177.6M (est)Novo Biosciences, Inc. · Seed Raised $4.0M · modeled $177.6M (est)Korro Bio, Inc. · Seed Raised $4.0M · modeled $177.6M (est)ReGelTec, Inc. · Seed Raised $6.0M · modeled $177.6M (est)TamuroBio Inc. · Seed Raised $4.0M · modeled $177.6M (est)Initial Therapeutics, Inc. · Seed Raised $3.8M · modeled $168.3M (est)Helaina Inc · Seed Raised $4.4M · modeled $164.8M (est)Onchilles Pharma, Inc. · Seed Raised $3.6M · modeled $158.5M (est)UVision 360, Inc. · Seed Raised $4.6M · modeled $155.7M (est)Safeguard Biosystems Holdings Ltd · Seed Raised $3.5M · modeled $155.4M (est)Enable Medicine Inc. · Seed Raised $3.6M · modeled $152.1M (est)Newomics Inc. · Seed Raised $3.9M · modeled $148.7M (est)Single Cell Technology, Inc. (this company) Raised $2.5M · modeled $69.4M (est)Single Cell Technology, Inc.
CompanyStageRaised · realValue · estvs peer med.
Entac Medical, Inc.Seed$4.0M$177.6M2.77×
Novo Biosciences, Inc.Seed$4.0M$177.6M2.77×
Korro Bio, Inc.Seed$4.0M$177.6M2.77×
ReGelTec, Inc.Seed$6.0M$177.6M2.77×
TamuroBio Inc.Seed$4.0M$177.6M2.77×
Initial Therapeutics, Inc.Seed$3.8M$168.3M2.62×
Helaina IncSeed$4.4M$164.8M2.57×
Onchilles Pharma, Inc.Seed$3.6M$158.5M2.47×
UVision 360, Inc.Seed$4.6M$155.7M2.43×
Safeguard Biosystems Holdings LtdSeed$3.5M$155.4M2.42×
Enable Medicine Inc.Seed$3.6M$152.1M2.37×
Newomics Inc.Seed$3.9M$148.7M2.32×
Single Cell Technology, Inc. this companySeed$2.5M$69.4M1.08×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$324K2012-12-12$1.8M$17.9M85%
Pre-Seed$105K2012-12-12$583K$5.8M85%
Seed$2.1M2021-01-22$10.7M$69.4M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$324K2012-12-12
    • First recorded raise — entered as Pre-Seed.
    • 9 investors on this round.
  2. Pre-Seed$105K2012-12-12
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 3.1× smaller than the prior — bridge or down round.
    • 2 investors on this round.
  3. Seed$2.1M2021-01-22
    • Raised again after 97 mo — slower than the ~14 mo sector norm.
    • Round 20.3× larger than the prior — scaling up.
    • Revenue band moved $0–$1M → $1M–$5M.
    • Switched to Rule 506(b) (was Rule 06).
    • 15 investors on this round.
Intelligence
2025 ~Q1
Modeled next raise · ~49mo cadence
$6.4M
Modeled next size est.range $4.2M$10.3M
20.3×
Last step-up
$303K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
ROBERT R. TUFTS8 other2012-12
Chun-Nan Chen2021-01
CHUN-NAN O CHEN2012-12
David O Sasseen2021-01
JAMES O BOWLBY2012-12
James O Bowlby, Jr.2021-01
Jun O Tien2021-01
RAMIN R NAJAFI2012-12
RICHARD O JORGENSEN2012-12
Yen-Ming O Hsu2021-01
Registry & provenance

Single Cell Technology, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1565042
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Lab7 Systems, Inc.BiotechnologySeed$2.5M$66.6Msame sector · same stage
Psilera IncBiotechnologySeed$2.5M$63.8Msame sector · same stage
Pocared Diagnostics, Ltd.BiotechnologySeed$2.5M$76.9Msame sector · same stage
Cyterix Pharmaceuticals Inc.BiotechnologySeed$2.4M$66.6Msame sector · same stage
Intact Vascular, LlcBiotechnologySeed$2.4M$55.5Msame sector · same stage
XCR Diagnostics IncBiotechnologySeed$2.4M$79.9Msame sector · same stage
NuShores Biosciences LLCBiotechnologySeed$2.6M$64.3Msame sector · same stage
Alchemia LTDBiotechnologySeed$2.6M$62.9Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Cell Microsystems, Inc.BiotechnologySeries A$52.4M90%
Cellular Biomedicine Group, Inc.BiotechnologySeries B$1.2B88%
One Health Group, Inc.BiotechnologySeries A$21.0M88%
SingleTimeMicroneedles, Inc.BiotechnologyPre-Seed$2.2M87%
Cell Source, Inc.BiotechnologySeries A$113.9M87%
CytoBioscience, Inc.BiotechnologySeries B$60.7M86%
Personalized Stem Cells, Inc.BiotechnologySeed$70.4M86%
Cell Point, LLCBiotechnologySeries B$99.8M86%
Frequently asked
How much funding has Single Cell Technology, Inc. raised?
Single Cell Technology, Inc. has raised approximately $2.5M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Single Cell Technology, Inc.'s estimated valuation?
Provath's modeled valuation for Single Cell Technology, Inc. is approximately $69.4M (modeled range $1.5M–$467.9M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Single Cell Technology, Inc. at?
Single Cell Technology, Inc.'s latest modeled financing stage is Seed. Its most recent recorded round closed around Fri Jan 22.
What does Single Cell Technology, Inc. do and where is it based?
Single Cell Technology, Inc. operates in the Biotechnology sector, based in SAN JOSE.
Explore related

See where Single Cell Technology, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Single Cell Technology, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.